In addition, sintilimab (a programmed cell death protein-1 inhibitor) plus bevacizumab or biosimilar (a vascular endothelial growth factor inhibitor) combination therapy has been upgraded as a first-line treatment (grade II) recommendation for advanced HCC in the Guidelines of the Chinese Society of Clinical Oncology Immune Checkpoint Inhibitor Clinical Practice 2021[5]. Here, VEGFA is linked to hepatocellular carcinoma.